Turoctocog alfa (recombinant factor VIII). Manufacturing, characteristics and clinical trial results.

Tiede, A; Klamroth, R; Oldenburg, J

Turoctocog alfa (recombinant factor VIII). Manufacturing, characteristics and clinical trial results.

Tiede, A; Klamroth, R; Oldenburg, J.

Affiliation

Tiede A; Prof. Dr. med. Andreas Tiede, Department of Haematology, Haemostasis, Oncology and Stem-Cell Transplantation, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany Tel. +49/(0)511/532 84 88, Fax +49/(0)511/532 41 46, tiede.andreas@mh-hannover.de.

Hamostaseologie ; 35(4): 364-71, 2015.

Article in En | MEDLINE | ID: mdl-26271775

Subject(s)

Drug Compounding/methods; Factor VIII/administration & dosage; Factor VIII/chemical synthesis; Hemophilia A/drug therapy; Hemophilia A/prevention & control; Protein Engineering/methods; Adolescent; Child; Child, Preschool; Dose-Response Relationship, Drug; Evidence-Based Medicine; Factor VIII/genetics; Female; Hemophilia A/diagnosis; Hemostatics/administration & dosage; Hemostatics/chemical synthesis; Humans; Infant; Infant, Newborn; Male; Treatment Outcome

Key words

Factor VIII; NovoEight™; haemophilia A; turoctocog alfa

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Factor VIII / Protein Engineering / Drug Compounding / Hemophilia A Type of study: Clinical_trials / Diagnostic_studies Limits: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male / Newborn Language: En Journal: Hamostaseologie Year: 2015 Document type: Article Country of publication: Germany

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google